Golfer247 - The latest news and products from the world of golf
Main Menu | News By Date | News By Supplier | News By Category | About Us
 

BTG SUCCESSFULLY DEFENDS KEY PATENT FOR GSM AND 3G VALUE ADDED SERVICES
07 October 2006 - BTG

BTG, the global technology commercialisation company, today announced the decision by the European Patent Office to uphold its patent relating to GSM, GPRS and 3G mobile communications. The Patent had been opposed by leading SIM Card manufacturers, following its grant in 1998.

BTG, the global technology commercialisation company, today announced the decision by the European Patent Office to uphold its patent relating to GSM, GPRS and 3G mobile communications. The Patent had been opposed by leading SIM Card manufacturers, following its grant in 1998.

The successful resolution of the patent’s validity will mean that BTG is now in a position to actively enforce its global IP rights to this widely used technology.

The technology covered by BTG’s patent builds on existing GSM network infrastructures and handsets, providing a more powerful SIM card that can be remotely updated to securely provide administration features and / or value added services over-the-air. The market for these powerful SIM cards is growing rapidly. In 2001 it was estimated that 160 million of these SIM cards were shipped, and industry leaders Schlumberger forecast that 560 million cards are expected to be shipped by network operators over the next two years.

Commenting on the recent Opposition outcome, Anthony V. Lando, Executive Vice President & Director of BTG’s Electronics, Engineering & Information Technologies division said “We are delighted to have successfully defended our rights to this invention, following a lengthy opposition by the major industry leaders. The EPO’s decision underlines the strength of the IP and the current widespread use of this technology presents a great business opportunity for BTG.”

http://www.btgplc.com

About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively.


More News:
  • For October 2006
  • From BTG
  • For Polymer OLED Devices

 

©2008 New Materials International